Michael Makris/LinkedIn
Jun 18, 2026, 06:43
Michael Makris: Will New Anti-TFPI Drug Armocibat Behaves any Different to Concizumab or Marstacimab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn:
“A Chinese company called Suzhou Alphamab is making an anti-TFPI drug called armocibat, for use in haemophilia with and without inhibitors.
The drug is in phase III at present.
They have just signed a license agreement for a Russian company called Nanolek to produce the drug.
I have no reason to believe that armocibat behaves any different to concizumab or marstacimab, but I hope they have safety surveillance systems to monitor for thrombosis when this drug is no longer in clinical trials.”
Stay updated with Hemostasis Today.
-
Nov 12, 2026, 09:35Factor XIa Inhibition Enters Clinical Practice With First FDA Approval
-
Nov 12, 2026, 09:30Roshni Kulkarni: A New Hope for Preventing Recurrent Stroke
-
Nov 12, 2026, 09:17Gashaw Arega Mekonnen: Jimma Moments – A Shared Mission for Childhood Cancer Care
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies